CD38: Modulating Histone Methyltransferase EZH2 Activity in SLE

Paramita Chakraborty1, Shikhar Mehrotra1

  • 1Department of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.

Trends in Immunology
|February 17, 2020
PubMed

To keep autoreactive T cells under control in SLE patients, immunosuppressive regimens are used, which can increase susceptibility to bacterial and viral infections. Recently, Katsuyama et al., demonstrated that the CD38/NAD/Sirtuin1/EZH2 axis reduces cytolytic CD8+ T cell function and might be targeted to overcome incidence of infections.